Key result
Gemfibrozil lowered serum triglyceride concentrations by 49% but did not improve glucose intolerance, insulin resistance, or elevated plasma PAI-1 activity in men with hypertriglyceridaemia.
Why the study?
Does gemfibrozil improve glucose tolerance, insulin sensitivity, and plasma PAI-1 activity in middle-aged non-diabetic men with moderate hypertriglyceridaemia?
Population
Middle-aged non-diabetic men with moderate primary hypertriglyceridaemia
Comparison
Gemfibrozil 600 mg oral twice a day for 12 months vs Single-blinded 2-month placebo phase
Design
Cohort, single-blinded (during the 2-month placebo phase)
Follow-up
12 months
Authors
Loading...
Gemfibrozil may not improve insulin resistance or PAI-1 despite triglyceride reduction; leaves open fibrate metabolic effects in hypertriglyceridaemia.
Does gemfibrozil improve glucose tolerance, insulin sensitivity, and plasma PAI-1 activity in middle-aged non-diabetic men with moderate hypertriglyceridaemia?
While gemfibrozil effectively lowers triglycerides and raises HDL, it does not improve glucose intolerance, insulin resistance, or elevated PAI-1 activity in patients with hypertriglyceridemia.
A. Asplund‐Carlson (1996) studied Primary hypertriglyceridaemia. Gemfibrozil vs. Placebo (patients served as their own controls) was evaluated on Serum triglyceride concentration. Gemfibrozil lowered serum triglyceride concentrations by 49% but did not improve glucose intolerance, insulin resistance, or elevated plasma PAI-1 activity in men with hypertriglyceridaemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: